The use of non-steroidal anti-inflammatory drugs (NSAID) is associated with a number of gastrointestinal and other adverse effects. Introduction of selective cyclooxygenase-2 (COX-2) inhibitors at the end of the 20th century raised hopes for a substantial reduction in the rate of serious events such as upper gastrointestinal ulcers, bleeding and perforations. In 2004 and 2005, predictions of so...

Non-steroidal anti-inflammatory drugs (NSAIDs) are the competitive inhibitors of cyclooxygenase (COX), the enzyme which mediates the bioconversion of arachidonic acid to inflammatory prostaglandins (PGs). Their use is associated with the side effects such as gastrointestinal and renal toxicity. The therapeutic anti-inflammatory action of NSAIDs is produced by the inhibition of COX-2, while the ...

Coxibs such as celecoxib, rofecoxib and valdecoxib are introduced as selective COX-2 inhibitors to the market. It has been reported that inhibition of COX-2 beside traditional effects of NSAIDs, reduces the risk of colorectal, breast and lung cancers and slow the progress of Alzheimer’s disease. Zarghi et al. reported 8-benzoyl-2-(4-(methylsulfonyl)phenyl)quinoline-4-carboxylic acid (AZGH 102) ...

Non-steroidal anti-inflammatory drugs (NSAIDs) are the competitive inhibitors of cyclooxygenase (COX), the enzyme which mediates the bioconversion of arachidonic acid to inflammatory prostaglandins (PGs). Their use is associated with the side effects such as gastrointestinal and renal toxicity. The therapeutic anti-inflammatory action of NSAIDs is produced by the inhibition of COX-2, while the ...

AIM The present meta-analysis attempted to assess whether an unfavourable cardiovascular risk profile could be identified in the case of two COX2 selective inhibitors (COXIBs), namely celecoxib and etoricoxib. Based on the data from the literature, our meta-analysis aimed to assess the probability of major cardiovascular events reported with the use of celecoxib or etoricoxib and compare this w...

Abstract Nonsteroidal anti-inflammatory drugs (NSAIDs) and coxibs are traditional medicines for the treatment of inflammation, yet associated with serious side effects. Hence, need discovering novel compounds valuable clinical benefits is great importance. In this study, 18 derivatives p-nitrophenyl hydrazones were docked against COX-2, 5-LOX, H+/K+ ATPase, followed by predicting their drug-lik...

It is now 50 years since the first discovery by Dr (now Professor) Stewart Adams (of the Boots Pure Drug Company, Nottingham, UK) of the pharmacological effects of the non-steroidal anti-inflammatory drug (NSAID), ibuprofen, in a guinea pig model of skin inflammation. It is now over 40 years since this drug was introduced into clinical use at doses of 1800–2400 mg ⁄ d for the treatment of arthr...

introduction: recent anti-inflammatory group of medications include the introduction of cyclooxygenase-ii inhibitors such as coxibs. these agents offer potentially significant advantages because of their realive lack of gastrointestinal irritation. the aim of this study was to evaluate the effect third molar surgery. methods and materials: this study was a double, randomized, cross over, clinic...